Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874924 | 0.95 | SLC1A5 (0.38) | SLC1A5CYP3A4SLC7A5CYP1A2IDO1 | |
| Aspartic Acid SCHEMBL7582142 | 0.91 | SLC1A5 (0.34) | SLC1A5CYP3A4SLC7A5CYP1A2IDO1 | |
| Glutamic Acid SCHEMBL4229342 | 0.89 | CYP1A2 (0.43) | SLC1A5CYP3A4SLC7A5CYP1A2IDO1 | |
| Histidine SCHEMBL27926628 | 0.89 | SLC7A5 (0.36) | SLC1A5CYP3A4SLC7A5CYP1A2IDO1 | |
| Histidine SCHEMBL2763245 | 0.88 | SLC7A5 (0.43) | CYP3A4SLC7A5CYP1A2 | |
| Histidine SCHEMBL1801721 | 0.88 | SLC7A5 (0.43) | CYP3A4SLC7A5CYP1A2 | |
| Histidine SCHEMBL56857 | 0.88 | SLC7A5 (0.43) | CYP3A4SLC7A5CYP1A2 | |
| Histidine SCHEMBL8027991 | 0.88 | SLC7A5 (0.43) | CYP3A4SLC7A5CYP1A2 | |
| Histidine SCHEMBL1136528 | 0.88 | SLC7A5 (0.43) | CYP3A4SLC7A5CYP1A2 | |
| Histidine SCHEMBL892614 | 0.88 | SLC7A5 (0.43) | CYP3A4SLC7A5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213509-A1 | LIPID NANOPARTICLE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-07-07 | — | — | US | disclosed |
| EP-3967649-A1 | LIPID NANOPARTICLE | National University Corporation Hokkaido University (JP) | 2022-03-16 | — | — | EP | disclosed |
| CN-114174522-A | Lipid nanoparticles | 国立大学法人北海道大学 | 2022-03-11 | — | — | CN | disclosed |
| EP-1399221-B1 | COMPOSITIONS COMPRISING OESTRONE-3-O-SULPHAMATE AND TRAIL (TNF-RELATED APOPTOSIS INDUCING LIGAND) | STERIX LTD (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-7211246-B2 | Compositions comprising oestrone-3-0-sulphamate and trail (TNF-related apoptosis inducing ligand) | STERIX LIMITED (GB) | 2007-05-01 | — | — | US | disclosed |
| US-20040166090-A1 | Compositions comprising oestrone-3-0-sulphamate and trail (TNF-related apoptosis inducing ligand) | STERIX LIMITED (GB) | 2004-08-26 | — | — | US | disclosed |
| EP-1399221-A1 | COMPOSITIONS COMPRISING OESTRONE-3-O-SULPHAMATE AND TRAIL (TNF-RELATED APOPTOSIS INDUCING LIGAND) | Sterix Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098511-A1 | COMPOSITIONS COMPRISING OESTRONE-3-0-SULPHAMATE AND TRAIL (TNF-RELATED APOPTOSIS INDUCING LIGAND) | STERIX LIMITED (GB) | 2002-12-12 | — | — | WO | disclosed |
| WO-2001019373-A2 | METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| EP-0998300-A1 | METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-10 | — | — | EP | disclosed |
| US-6054487-A | ADMINISTERING AN INTERLEUKIN-ONE BETA CONVERTING ENZYME SUFFICIENT TO INHIBIT PRODUCTION OF GAMMA-INTERFERON | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| WO-1998041232-A2 | COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040166090-A1 | Compositions comprising oestrone-3-0-sulphamate and trail (TNF-related apoptosis inducing ligand) | CASP3, TNFRSF1A, BAX | SLC1A5 3793/4885CYP3A4 1063/4885SLC7A5 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.